What indicators should be monitored during treatment with daprodustat?

In the treatment of chronic kidney disease-related anemia, the efficacy and safety of daprodustat are highly dependent on the standardized management of monitoring indicators. Before taking medication, a comprehensive assessment of the patient's anemia and iron stores is required. Hemoglobin level is the main observation indicator, and other causes of anemia should be excluded, such as vitamin B12 or folic acid deficiency, chronic inflammatory states, or bleeding factors. Iron metabolism indicators include serum ferritin and transferrin saturation. For patients with serum ferritin lower than 100ng/ml or transferrin saturation lower than 20%, iron supplements should be supplemented to ensure drug efficacy. Most patients with chronic kidney disease still require iron supplementation during treatment to maintain stable hemoglobin levels.

Liver function monitoring is also an essential part. Before initiating daporostat, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and total bilirubin should be assessed. If the patient develops symptoms or signs related to liver disease during treatment, the liver function should be reviewed immediately and the dose should be adjusted or the medication should be suspended as appropriate. In addition, blood pressure monitoring is particularly important for patients with hypertension, because daprostat may affect hemodynamics and blood pressure should be ensured to be within a controllable range.

Monitoring of cardiovascular events is equally important, including heart rate, blood pressure, and assessment of potential thrombotic risk. The frequency of monitoring and interventions can be determined based on the patient's past history of cardiovascular disease. At the same time, attention should be paid to the dynamic changes in hematological indicators, such as hematocrit and complete blood count, to ensure that hemoconcentration or abnormal fluctuations do not occur during treatment.

Regular monitoring of these indicators will not only help to judge the efficacy of daprexostat, but also identify potential risks in a timely manner, enable individualized dose adjustment, and improve medication safety. Through scientific management of monitoring data, patients can improve hemoglobin while reducing the probability of cardiovascular, liver and kidney adverse events, and optimizing the overall treatment effect of chronic kidney disease anemia.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat